This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024. Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi. Disclosure Policy All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Faculty/Planner Disclosures Co-Chair/Planner James D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen. Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics. Data Safety Monitoring Board for Sanofi. Co-Chair/Planner Sabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation. Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc. Planning Committee and Reviewer Disclosures Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.